Erratum (DOI:10.1053/j.seminoncol.2007.11.005);Forodesine Treatment and Post-Transplant Graft-Versus-Host Disease in Two Patients With Acute Leukemia: Facilitation of Graft-Versus-Leukemia Effect?

Seminars in Oncology

Volumn 34, Issue SUPPL. 5, 2007, Pages 92-

  Gore, Lia ^a   Stelljes, Mattias ^b   Quinones, Ralph ^a  

^a Children's Hospital Colorado   (United States)

^b UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARAGINASE; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; CYTARABINE; DAUNORUBICIN; ETOPOSIDE; FORODESINE; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; METHOTREXATE; METHYLPREDNISOLONE; MULTIVITAMIN; OMEPRAZOLE; PREDNISOLONE; PREDNISONE; PURINE NUCLEOSIDE PHOSPHORYLASE INHIBITOR; UNCLASSIFIED DRUG; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CASE REPORT; CHILD; COMPUTER ASSISTED TOMOGRAPHY; DRUG CYTOTOXICITY; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG MEGADOSE; FEMALE; FLOW CYTOMETRY; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GASTROINTESTINAL SYMPTOM; GRAFT VERSUS HOST REACTION; GRAFT VERSUS LEUKEMIA EFFECT; HISTOLOGY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTIOUS COMPLICATION; LEUKEMIA; LIVER BIOPSY; LIVER TOXICITY; MALE; PNEUMOCYSTOSIS; PRIORITY JOURNAL; REMISSION; SIDE EFFECT; T CELL LEUKEMIA; TREATMENT OUTCOME; TUMOR VOLUME;

EID: 37149015702     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2007.12.012     Document Type: Erratum

References (13)

1. Furman R.R., Gore L., Ravandi F., et al. Forodesine IV (BCX-1777) is clinically active in relapsed/refractory T-cell leukemia: Results of a phase II study (interim report). Blood 108 suppl 1 (2006) 524a (abstr 1851)
2. Furman R.R., Gandhi V., Bennett J.C., et al. Intravenous forodesine (BCX-1777), a novel purine nucleoside phosphorylase (PNP) inhibitor, demonstrates clinical activity in phase I/II studies in patients with B-cell acute lymphoblastic leukemia. Blood 104 suppl 1 (2004) 750a (abstr 2743)
3. Furman R.R., Iosava G., Isola L., et al. Forodesine (Fodosine™), a PNP inhibitor active in relapsed or refractory T-cell leukemia patients (phase II study). Blood 106 suppl 1 (2005) 259a (abstr 881)
4. Nachman J., Siebel N., Sather H., et al. Outcome for adolescent and young adults 16-21 years of age (AYA) with ALL treated on the Children's Cancer Group (CCG) 1961 study. Blood 104 suppl 1 (2004) 196a (abstr 683)
5. Bantia S., and Kilpatrick J.M. Purine nucleoside phosphorylase inhibitors in T-cell malignancies. Curr Opin Drug Discov Devel 7 (2004) 243-247
6. Viegas T.X., Omura G.A., Stoltz R.R., et al. Pharmacokinetics and pharmacodynamics of Peldesine (BCX-34), on activation and proliferation of normal human lymphoid cells. J Clin Pharmacol 40 (2000) 410-420
7. Bantia S., Miller P.J., Parker C.D., et al. Purine nucleoside phosphorylase inhibitor BCX-1777 (Immucillin-H)-a novel potent and orally active immunosuppressive agent. Int Immunopharmacol 1 (2001) 1199-1210
8. Sullivan K.M. Graft-versus-host disease. In: Thomas E.D. (Ed). Hematopoietic Cell Transplantation. Ed 2 (1999), Blackwell Science, Boston, MA 515-536
9. Copelan E.A. Hematopoietic stem-cell transplantation. N Engl J Med 354 (2006) 1813-1826
10. Socie G. Current issues in allogeneic stem cell transplantation. Hematology 10 suppl 1 (2005) 63 (abstr)
11. Zeng D., Lan F., Hoffman P., et al. Suppression of graft-versus-host disease by naturally occurring regulatory T cells. Transplantation 77 (2004) S9-S11
12. + immunoregulatory cells in the graft-versus-host reaction: CD8 T cells activate dendritic cells to secrete interleukin-12/interleukin-18 and induce T helper 1 autoantibody. Immunology 109 (2003) 476-486
13. Bantia S., Miller P.J., Parker C.D., et al. Comparison of in vivo efficacy of BCX-1777 and cyclosporine in xenogeneic graft-vs.-host disease: The role of the dGTP in antiproliferative action of BCX-1777. Int Immunopharmacol 2 (2002) 913-923